A Phase 2 interventional study of MVA-NP+M1 and Saline in Influenza, sponsored by Barinthus Biotherapeutics. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-18.
Sponsored by Barinthus Biotherapeutics · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Influenza, Human with a site in Belgium — 4 open to participants now, 5 under way, 2 of them phase 3. Influenza, Human · Belgium.
Among the 106 studies in Influenza, Human with a site in Belgium, this one is the 61st largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2019, is one of 33 in phase 2, and was the 85th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →4 of the 106 studies in Influenza, Human with a site in Belgium are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Belgium, United States, Argentina and 36 more countries
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
UMC Utrecht · Sites in Belgium, United States, Australia and 26 more countries
Ages 28 days+
Cyril Barbezange · Sites in Belgium
Ages 18+ · Healthy volunteers
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 35 · Phase 3 36 · Phase 4 8
First in 2003; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 145 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 243 across the 97 interventional studies, 241 across the 9 observational. Of the 99 that completed or were terminated, 41 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 106 have an industry lead sponsor. The 10 most frequent:
Barinthus Biotherapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Barinthus Biotherapeutics has 3 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
2 of the studies in Influenza, Human with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT03748069Universitaire Ziekenhuizen KU LeuvenInfluenza Associated Aspergillosis In-depth Investigation | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 106 studies in Influenza, Human with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.
The study consists of an outpatient vaccination phase (155 participants), and at least 2 months later an inpatient challenge phase (134 participants). Participants are randomized 93:62 to receive either MVA-NP+M1 or Placebo. Up to 20 participants will be challenged over several 3-week blocks, and the remainder at the final 3-week block for a total of 80 MVA-NP+M1 and 54 Placebo recipients challenged.
Inclusion Criteria:
A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:
i. male partner who is sterile (vasectomised) prior to the female participants entry into the study and is the sole sexual partner for the female participant; ii. hormonal (oral, intravaginal, transdermal, implantable or injectable); iii. an intrauterine hormone-releasing system (IUS); iv. an intrauterine device (IUD) with a documented failure rate of \< 1%; v. bilateral tubal occlusion.
Exclusion Criteria:
EXCLUSION (CHALLENGE PERIOD ONLY)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\^6 TCID50/ml)
Biological: MVA-NP+M1 · Biological: H3N2 (A/Belgium/2417/2015)
Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10\^6 TCID50/ml)
Biological: Saline · Biological: H3N2 (A/Belgium/2417/2015)
Drug page: MVA-NP+M1Studies of MVA-NP+M1MVA-NP+M1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Trial Vaccine
Sodium Chloride Placebo
Drug page: Influenza A virus subtype H3N2Studies of Influenza A virus subtype H3N2Influenza A virus subtype H3N2 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Challenge Agent
Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR
Measure of nasopharyngeal viral shedding during challenge; recorded as viral area under curve (vAUC) as determined by quantitative real time polymerase chain reaction (qRT-PCR). vAUC is calculated by plotting the log viral particles number/ml for each time point against time and is using the trapezoidal rule.
Time frame: Throughout 9 days (Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day9, Day10) after viral Inoculation (Day1) of the challenge phase. Nasal swabs taken twice a day (b.i.d) at least 8 hours apart.
Number and Percentage of Virologically Confirmed Influenza-Like Illness
Incidence (frequency tabulation) of laboratory-confirmed influenza-like illness compared between vaccine and placebo arms Virologically confirmed influenza-like illness (ILI) is defined as having respiratory or flu-like symptom occurring on two consecutive days, along with a positive qPCR or qCulture result.
Time frame: 9 days from day 2 to day 10
Percentage of Participants With Attack Rate of Challenge Agent (qRT-PCR)
The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qRT-PCR within the timespan of two consecutive days
Time frame: 9 days from day 2 to day 10
Percentage of Participants With Quantitative Culture Attack Rate of Challenge Agent (qCulture)
The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qCulture within the timespan of two consecutive days
Time frame: 9 days from day 2 to day 10
Time to Start of Viral Shedding (qPCR) From Virus Inoculation
The Time to Start of Viral Shedding (qPCR) is calculated as (datetime of first of two positive swabs (qPCR) within 2 consecutive days - challenge datetime)/(60\*60)
Time frame: 9 days from day 2 to day 10
Time to Start of Viral Shedding (qCulture) From Virus Inoculation
Time to Start of Viral Shedding (qCulture) is calculated as (datetime of first of two positive swabs (qCulture) within 2 consecutive days - challenge datetime)/(60\*60)
Time frame: 9 days from day 2 to day 10
Peak Viral Shedding (qPCR) After the Virus Inoculation
This is measured by the highest viral load concentration by qPCR
Time frame: 9 days from Day 2 to Day 10
Peak Viral Shedding (qCulture) After Virus Inoculation
This is measured by the highest viral load concentration by qCulture.
Time frame: 9 days from day 2 to day 10
Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation
This is calculated as (datetime of highest viral load concentration (qPCR) - challenge datetime)/(60\*60)
Time frame: 9 days from day 2 to day 10
Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation
This is calculated as (datetime of highest viral load concentration (qCulture) - challenge datetime)/(60\*60)
Time frame: 9 days from day 2 to day 10
Duration of Viral Shedding (qPCR) After the Virus Inoculation
It is calculated as (datetime of first negative swab (qPCR) following the last positive swab (qPCR) - datetime of first positive of two positive swabs (qPCR) within 2 consecutive days)/(60\*60)
Time frame: 9 days from day2 to day10
Duration of Viral Shedding (qCulture) After the Virus Inoculation
It is calculated as (datetime of first negative swab (qCulture) following the last positive swab (qCulture) - datetime of first positive of two positive swabs (qCulture) within 2 consecutive days)/(60\*60)
Time frame: 9 days from day 2 to day 10
Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC)
Total symptom scores were compared for MVA-NP+M1 vs. Placebo from Day1 to Day11 post-challenge as AUC of composite score. Symptoms were collected twice a day (lymphadenopathy once a day) on a Symptom Score Card(SSC). SSC recorded scores for each 16 general (gastrointestinal/body systemic) and 12 local (upper/lower respiratory tract) symptoms, on the scale per timepoint (for example Day2,AM). Participants rated the severity of symptoms, higher scores indicating a more severe symptom. The scores ranged from 0 to 3 (0:symptom free, 1:mild, 2:moderate, 3:severe).The SSC also contained the question whether the subject felt well to go to work "today" (yes/no). The Overall SSC score was calculated, as the Arithmetic Mean of the Scores collected across all 28 items on the card per Timepoint and ranged from 0 to maximum 3. The SSC AUC \[0-11 days\] was derived based on the Overall SSC score against time (\*hour), using the linear trapezoidal rule and it ranged from 0 to 110 Score\*hour.
Time frame: 11 days from Day 1 to Day 11
Total Days of Fever
Total days of fever for MVA-NP+M1 vs. Placebo
Time frame: 11 days from Day 1 to Day 11
Average Total Mucus Production
Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo. Total mucus production was only be calculated in case all tissues were returned (sum of clean and used tissues returned should be 20 tissues for each bag).
Time frame: 11 days from Day 1 to Day 11
T Cell Responses as Defined by ELISpot Assay in Relation to the Primary Endpoint, Symptom Scores and Influenza Incidence
T Cell Response was assessed for IFN gamma and granzyme B, on the peripheral blood mononuclear cell using a double-colour enzymatic ELISpot assay. For each of them, three stimulation antigens were assessed: nucleoprotein NP, matrix1 M1 and a negative control, dimethyl sulfoxide (DMSO). The number of spot-forming T cell colonies per well (i.e. 200,000 cells) +/- standard deviation for the total response to NP+M1 is reported. The endpoint was recorded as the mean spot-forming units per million peripheral blood mononuclear cells in the peptide-stimulated wells minus the mean DMSO control wells for the sample. T cell responses over time (sampling timepoints) were then assessed in relation to the primary endpoint, symptom scores, and influenza incidence.
Time frame: 3 months (day 0, day 8 and day 28 of the vaccination period and day -1 and day 28 of the challenge period)
Number of Participants With MVA-NP+M1 Vaccination Related Adverse Events and Symptoms, Measured by Self-reported Symptoms
Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries
Time frame: 7 days following vaccination
Number of Participants With H3N2 Challenge Related Adverse Events and Symptoms, Measured by Self-reported Symptoms
Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring
Time frame: 17 days following vaccination
Severity of Individual Symptoms for MVA-NP+M1 vs. Placebo
Severity of individual self-reported symptoms for MVA-NP+M1 vs. Placebo
Time frame: 11 days
Total Symptom Score Time to Start, Time to Peak and Duration
Time to start; time to peak and duration of total self-reported symptom score, regardless of take rate Influenza Symptom Score Card of FLU010 - Solicited symptoms for generalized, and upper and lower respiratory tract symptoms scored by severity (0: absent, 1: mild, 2: moderate, or 3: severe).
Time frame: 11 days
Correlation of T Cell Phenotypes With Illness Outcomes
Correlation of antigen specific T Cell phenotypes with illness outcomes
Time frame: 3 months
Vaccination Effect on Antibody Responses by ELISpot and ICS Assays
Antibody responses of MVA-NP+M1 vs Placebo following influenza challenge measured by ELISpot and Intracellular Cytokine Staining (ICS)
Time frame: 3 months
The study was conducted at the SGS Clinical Pharmacology Unit in Antwerp, Belgium.
| Milestone | MVA-NP+M1 & H3N2 Challenge Virus | Saline Placebo & H3N2 Challenge Virus |
|---|---|---|
| Started | 87 | 58 |
| Completed | 71 | 46 |
| Not completed | 16 | 12 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Challenge criteria not met / sponsor decision | 9 | 7 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
Measure of nasopharyngeal viral shedding during challenge; recorded as viral area under curve (vAUC) as determined by quantitative real time polymerase chain reaction (qRT-PCR). vAUC is calculated by plotting the log viral particles number/ml for each time point against time and is using the trapezoidal rule.
| hour*Log10 Viral Particles/ ml | MVA-NP+M1 (ITT) | Placebo (ITT) | MVA-NP+M1 (PP) | Placebo (PP) | MVA-NP+M1 (Challenge) | Placebo (Challenge) |
|---|---|---|---|---|---|---|
| Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR | 649.7 (552.7 to 746.7) | 726.1 (604.0 to 848.2) | 646.5 (548.3 to 744.7) | 726.1 (604.0 to 848.2) | 649.7 (552.7 to 746.7) | 726.1 (604.0 to 848.2) |
Incidence (frequency tabulation) of laboratory-confirmed influenza-like illness compared between vaccine and placebo arms Virologically confirmed influenza-like illness (ILI) is defined as having respiratory or flu-like symptom occurring on two consecutive days, along with a positive qPCR or qCulture result.
| Participants | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| Virologically confirmed Influenza-like Illness | 43 | 29 |
| No Virologically Confirmed Influenza-like Illness | 28 | 18 |
The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qRT-PCR within the timespan of two consecutive days
| percentage of participants | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| qPCR-confirmed influenza | 90.1 (80.7 to 95.9) | 97.9 (88.7 to 99.9) |
| No qPCR influenza | 9.9 (4.1 to 19.3) | 2.1 (0.1 to 11.3) |
The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qCulture within the timespan of two consecutive days
| percentage | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| qCulture confirmed influenza | 77.5 (66.0 to 86.5) | 85.1 (71.7 to 93.8) |
| No qCulture-confirmed influenza | 22.5 (13.5 to 34.0) | 14.9 (6.2 to 28.3) |
The Time to Start of Viral Shedding (qPCR) is calculated as (datetime of first of two positive swabs (qPCR) within 2 consecutive days - challenge datetime)/(60\*60)
| hours | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| Time to Start of Viral Shedding (qPCR) From Virus Inoculation | 24.40 (24.30 to 24.50) | 24.30 (24.20 to 24.50) |
Time to Start of Viral Shedding (qCulture) is calculated as (datetime of first of two positive swabs (qCulture) within 2 consecutive days - challenge datetime)/(60\*60)
| hours | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| Time to Start of Viral Shedding (qCulture) From Virus Inoculation | 35.9 (35.60 to 48.00) | 47.6 (24.70 to 48.50) |
This is measured by the highest viral load concentration by qPCR
| Log10 Viral Particles/ ml | MVA-NP+M1 (ITT) Successful Attack | Placebo (ITT) Successful Attack |
|---|---|---|
| Peak Viral Shedding (qPCR) After the Virus Inoculation | 5.876 (5.430 to 6.322) | 6.054 (5.521 to 6.587) |
This is measured by the highest viral load concentration by qCulture.
| Log10 Viral Particles/ ml | MVA-NP+M1 (ITT) Successful Attack | Placebo (ITT) Successful Attack |
|---|---|---|
| Peak Viral Shedding (qCulture) After Virus Inoculation | 4.073 (3.683 to 4.463) | 4.069 (3.442 to 4.695) |
This is calculated as (datetime of highest viral load concentration (qPCR) - challenge datetime)/(60\*60)
| hours | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation | 72.20 (60.00 to 96.00) | 107.90 (72.20 to 119.80) |
This is calculated as (datetime of highest viral load concentration (qCulture) - challenge datetime)/(60\*60)
| hours | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation | 83.40 (60.10 to 96.30) | 83.80 (60.10 to 96.40) |
It is calculated as (datetime of first negative swab (qPCR) following the last positive swab (qPCR) - datetime of first positive of two positive swabs (qPCR) within 2 consecutive days)/(60\*60)
| hours | MVA-NP+M1 (ITT) Successful Attack | Placebo (ITT) Successful Attack |
|---|---|---|
| Duration of Viral Shedding (qPCR) After the Virus Inoculation | 170.80 (157.08 to 184.52) | 172.47 (156.99 to 187.94) |
It is calculated as (datetime of first negative swab (qCulture) following the last positive swab (qCulture) - datetime of first positive of two positive swabs (qCulture) within 2 consecutive days)/(60\*60)
| hours | MVA-NP+M1 (ITT) Successful Attack | Placebo (ITT) Successful Attack |
|---|---|---|
| Duration of Viral Shedding (qCulture) After the Virus Inoculation | 118.19 (105.07 to 131.31) | 121.78 (106.33 to 137.23) |
Total symptom scores were compared for MVA-NP+M1 vs. Placebo from Day1 to Day11 post-challenge as AUC of composite score. Symptoms were collected twice a day (lymphadenopathy once a day) on a Symptom Score Card(SSC). SSC recorded scores for each 16 general (gastrointestinal/body systemic) and 12 local (upper/lower respiratory tract) symptoms, on the scale per timepoint (for example Day2,AM). Participants rated the severity of symptoms, higher scores indicating a more severe symptom. The scores ranged from 0 to 3 (0:symptom free, 1:mild, 2:moderate, 3:severe).The SSC also contained the question whether the subject felt well to go to work "today" (yes/no). The Overall SSC score was calculated, as the Arithmetic Mean of the Scores collected across all 28 items on the card per Timepoint and ranged from 0 to maximum 3. The SSC AUC \[0-11 days\] was derived based on the Overall SSC score against time (\*hour), using the linear trapezoidal rule and it ranged from 0 to 110 Score\*hour.
| Composite symptom score on scale*hour | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC) | 16.709 (11.568 to 21.850) | 20.432 (13.753 to 27.112) |
Total days of fever for MVA-NP+M1 vs. Placebo
| days | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| Total Days of Fever | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.1) |
Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo. Total mucus production was only be calculated in case all tissues were returned (sum of clean and used tissues returned should be 20 tissues for each bag).
| grams | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| Average Total Mucus Production | 31.09 (16.23 to 45.85) | 38.21 (16.78 to 59.63) |
T Cell Response was assessed for IFN gamma and granzyme B, on the peripheral blood mononuclear cell using a double-colour enzymatic ELISpot assay. For each of them, three stimulation antigens were assessed: nucleoprotein NP, matrix1 M1 and a negative control, dimethyl sulfoxide (DMSO). The number of spot-forming T cell colonies per well (i.e. 200,000 cells) +/- standard deviation for the total response to NP+M1 is reported. The endpoint was recorded as the mean spot-forming units per million peripheral blood mononuclear cells in the peptide-stimulated wells minus the mean DMSO control wells for the sample. T cell responses over time (sampling timepoints) were then assessed in relation to the primary endpoint, symptom scores, and influenza incidence.
| Spot-forming units per million | MVA-NP+M1 (ITT) | Placebo (ITT) |
|---|---|---|
| Baseline (Vaccination) | 230 ± 265 | 167 ± 157 |
| Day 8 (from Vaccination) | 645 ± 634 | 170 ± 144 |
| Day 28 (from Vaccination) | 566 ± 551 | 163 ± 160 |
| Day 0 Challenge Period | 460 ± 471 | 159 ± 132 |
| Day 28 Challenge Period | 561 ± 483 | 329 ± 220 |
Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries
| Participants | MVA-NP+M1 | Saline Placebo |
|---|---|---|
| TEAE | 36 | 18 |
| Solicited symptom | 84 | 24 |
| TEAE or solicited symptom | 85 | 34 |
| Local solicited symptom | 80 | 8 |
| Local Grade 3 solicited symptom | 2 | 0 |
| Systemic solicited symptom | 72 | 20 |
| Systemic Grade 3 solicited symptom | 2 | 0 |
| TEAE of special interest | 0 | 0 |
| Serious TEAE | 1 | 0 |
| Non-serious TEAE | 36 | 18 |
| Grade ≥3 TEAE | 1 | 0 |
| Grade ≥3 TE laboratory toxicity | 2 | 0 |
| Fatal TEAE | 0 | 0 |
| TEAE related to treatment | 10 | 4 |
| Serious TEAE related to treatment | 1 | 0 |
| Grade ≥3 TEAE related to treatment | 1 | 0 |
| TEAE for which the study was discontinued | 0 | 0 |
Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring
| Participants | MVA-NP+M1 (Challenge) | Placebo (Challenge) |
|---|---|---|
| TEAE | 30 | 21 |
| Solicited symptom | 62 | 40 |
| TEAE or solicited symptom | 65 | 42 |
| Local solicited symptom | 59 | 39 |
| Local Grade 3 solicited symptom | 0 | 0 |
| Systemic solicited symptom | 45 | 32 |
| Systemic Grade 3 solicited symptom | 0 | 0 |
| TEAE of special interest | 0 | 0 |
| Serious TEAE | 0 | 1 |
| Non-serious TEAE | 30 | 20 |
| Grade ≥3 TEAE | 0 | 2 |
| Grade ≥3 TE laboratory toxicity | 7 | 2 |
| Fatal TEAE | 0 | 0 |
| TEAE related to challenge | 7 | 5 |
| Serious TEAE related to challenge | 0 | 0 |
| Grade ≥3 TEAE related to challenge | 0 | 0 |
| TEAE for which the study was discontinued | 0 | 1 |
Severity of individual self-reported symptoms for MVA-NP+M1 vs. Placebo
Results for this outcome have not been posted.
Time to start; time to peak and duration of total self-reported symptom score, regardless of take rate Influenza Symptom Score Card of FLU010 - Solicited symptoms for generalized, and upper and lower respiratory tract symptoms scored by severity (0: absent, 1: mild, 2: moderate, or 3: severe).
Results for this outcome have not been posted.
Correlation of antigen specific T Cell phenotypes with illness outcomes
Results for this outcome have not been posted.
Antibody responses of MVA-NP+M1 vs Placebo following influenza challenge measured by ELISpot and Intracellular Cytokine Staining (ICS)
Results for this outcome have not been posted.
Collected over Any time during the study from the first administration of any study drug until the last study-related activity (the outpatient visit at 27 days ±3 days following the challenge or 6 months following vaccination ±14 days, whichever is longer). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MVA-NP+M1 (Vaccination Phase) | 0/87 (0%) | 1/87 (1.1%) | 36/87 (41.4%) |
| Saline Placebo (Vaccination Phase) | 0/58 (0%) | 0/58 (0%) | 18/58 (31%) |
| MVA-NP+M1 (Challenge Phase) | 0/71 (0%) | 0/71 (0%) | 30/71 (42.3%) |
| Saline Placebo (Challenge Phase) | 0/47 (0%) | 1/47 (2.1%) | 21/47 (44.7%) |
| Event | MVA-NP+M1 (Vaccination Phase) | Saline Placebo (Vaccination Phase) | MVA-NP+M1 (Challenge Phase) | Saline Placebo (Challenge Phase) |
|---|---|---|---|---|
| Acute PsychosisPsychiatric disorders | 0/87 | 0/58 | 0/71 | 1/47 |
| Foetal deathPregnancy, puerperium and perinatal conditions | 1/87 | 0/58 | 0/71 | 0/47 |
| Event | MVA-NP+M1 (Vaccination Phase) | Saline Placebo (Vaccination Phase) | MVA-NP+M1 (Challenge Phase) | Saline Placebo (Challenge Phase) |
|---|---|---|---|---|
| Back PainMusculoskeletal and connective tissue disorders | 3/87 | 0/58 | 4/71 | 6/47 |
| NasopharyngitisInfections and infestations | 6/87 | 4/58 | 0/71 | 0/47 |
| DiarrhoeaGastrointestinal disorders | 5/87 | 3/58 | 3/71 | 0/47 |
| HeadacheNervous system disorders | 5/87 | 2/58 | 2/71 | 1/47 |
| Abdominal PainGastrointestinal disorders | 1/87 | 0/58 | 0/71 | 2/47 |
| Skin IrritationSkin and subcutaneous tissue disorders | 2/87 | 1/58 | 3/71 | 1/47 |
| GastroenteritisInfections and infestations | 0/87 | 2/58 | 0/71 | 0/47 |
| Throat IrritationRespiratory, thoracic and mediastinal disorders | 3/87 | 2/58 | 0/71 | 0/47 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/87 | 0/58 | 2/71 | 0/47 |
| UrticariaSkin and subcutaneous tissue disorders | 3/87 | 1/58 | 2/71 | 0/47 |
| Age, Categorical(Participants) | MVA-NP+M1 & H3N2 Challenge Virus | Saline Placebo & H3N2 Challenge Virus | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 87 | 58 | 145 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | MVA-NP+M1 & H3N2 Challenge Virus | Saline Placebo & H3N2 Challenge Virus | Total |
|---|---|---|---|
| Median | 43.00 (18.5 to 55.9) | 41.25 (19.9 to 55.7) | 42.50 (18.5 to 55.9) |
| Sex: Female, Male(Participants) | MVA-NP+M1 & H3N2 Challenge Virus | Saline Placebo & H3N2 Challenge Virus | Total |
|---|---|---|---|
| Female | 47 | 31 | 78 |
| Male | 40 | 27 | 67 |
| Race/Ethnicity, Customized(Participants) | MVA-NP+M1 & H3N2 Challenge Virus | Saline Placebo & H3N2 Challenge Virus | Total |
|---|---|---|---|
| Asian | 2 | 0 | 2 |
| Black or African American | 4 | 0 | 4 |
| Middle Eastern | 0 | 1 | 1 |
| White | 81 | 57 | 138 |
| Region of Enrollment(participants) | MVA-NP+M1 & H3N2 Challenge Virus | Saline Placebo & H3N2 Challenge Virus | Total |
|---|---|---|---|
| Belgium | 87 | 58 | 145 |
| Smoking Status(Participants) | MVA-NP+M1 & H3N2 Challenge Virus | Saline Placebo & H3N2 Challenge Virus | Total |
|---|---|---|---|
| Ex-smoker | 27 | 18 | 45 |
| Non-smoker | 60 | 40 | 100 |
| Height(cm) | MVA-NP+M1 & H3N2 Challenge Virus | Saline Placebo & H3N2 Challenge Virus | Total |
|---|---|---|---|
| Median | 172.40 (153.2 to 193.3) | 172.30 (151.8 to 191.7) | 172.40 (151.8 to 193.3) |
| Weight(kg) | MVA-NP+M1 & H3N2 Challenge Virus | Saline Placebo & H3N2 Challenge Virus | Total |
|---|---|---|---|
| Median | 72.9 (53.2 to 118.8) | 75.15 (54.6 to 105.6) | 73.60 (53.2 to 118.8) |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in Dec 2019, 6 months.
Results were first posted in Mar 2021, 1 year 3 months after primary completion.
Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 6 months is below that.
Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MVA-NP+M1
Barinthus Biotherapeutics